# PTGS2

## Overview
PTGS2, also known as cyclooxygenase-2 (COX-2), is a gene that encodes the enzyme prostaglandin-endoperoxide synthase 2, a key player in the biosynthesis of prostanoids, including prostaglandins, from arachidonic acid. This enzyme is categorized as a cyclooxygenase and is primarily involved in the inflammatory response, making it a significant target for nonsteroidal anti-inflammatory drugs (NSAIDs) (Williams1996Prostaglandin). Unlike its constitutively expressed counterpart COX-1, COX-2 is inducible and is upregulated in response to inflammatory stimuli, mitogens, and physical stressors (Santulli2014Hormonal). The enzyme is predominantly localized in the endoplasmic reticulum and perinuclear envelope, where it plays a role in modulating gene transcription through the production of eicosanoids (Williams1996Prostaglandin). PTGS2 is implicated in various physiological and pathological processes, including inflammation, cancer progression, and reproductive functions, highlighting its importance in both health and disease (Cebola2015Epigenetics; Narumiya1999Prostanoid).

## Structure
The PTGS2 gene encodes the cyclooxygenase-2 (COX-2) enzyme, which plays a crucial role in the conversion of arachidonic acid to prostanoids. The COX-2 protein consists of 604 amino acids and shares 61% identity with COX-1 (Tanabe2002Cyclooxygenase). It functions as a homodimer, with each subunit containing an epidermal growth factor-like domain, a membrane-binding domain, and a catalytic domain that includes cyclooxygenase and peroxidase active sites (Alexanian2017Cyclooxygenase).

The enzyme's activity is regulated by various post-translational modifications, such as s-nitrosylation, glycosylation, ubiquitination, and phosphorylation. S-nitrosylation can increase COX-2 catalytic activity, while glycosylation targets the enzyme for degradation via endoplasmic reticulum-associated pathways. Ubiquitination marks COX-2 for proteasomal degradation, and phosphorylation modulates its activity (Alexanian2017Cyclooxygenase).

COX-2 also interacts with several proteins, such as ELMO1 and FYN, which regulate its activity through phosphorylation and protein-protein interactions (Alexanian2017Cyclooxygenase). These interactions and modifications are significant for understanding COX-2's role in physiological and pathophysiological processes, including inflammation and tumor growth (Alexanian2017Cyclooxygenase).

## Function
PTGS2, also known as cyclooxygenase-2 (COX-2), is an inducible enzyme that plays a significant role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation and pain signaling (Williams1996Prostaglandin). In healthy human cells, PTGS2 is typically expressed at low levels but can be upregulated in response to inflammatory, mitogenic, or physical stimuli such as oxidative stress (Santulli2014Hormonal). 

The enzyme is primarily active in the endoplasmic reticulum and the perinuclear envelope, suggesting a role in modulating transcription of target genes by distributing eicosanoid products to the nuclear compartment (Williams1996Prostaglandin). PTGS2 is involved in the synthesis of prostaglandin E2 (PGE2), which mediates important biological processes such as the proliferation and differentiation of articular chondrocytes and the modulation of immune responses (Valdes2008Genomewide). 

In addition to its role in inflammation, PTGS2 is crucial for normal physiological processes, including cartilage differentiation and proliferation, and it mediates the effects of vitamin D on cartilage (Valdes2008Genomewide). The enzyme's activity is also essential for reproductive functions, as evidenced by studies on COX-2-deficient mice, which show reproductive failures, indicating its importance in ovulation, fertilization, and early pregnancy processes (Narumiya1999Prostanoid).

## Clinical Significance
Alterations in the expression of the PTGS2 gene, also known as COX-2, are implicated in various diseases, particularly cancer and inflammatory conditions. Overexpression of PTGS2 is associated with cancer progression, including colorectal cancer (CRC) and gastric cancer. In CRC, PTGS2 overexpression leads to increased production of prostaglandin E2 (PGE2), which is linked to metastasis and poor prognosis. This overexpression is often due to DNA methylation changes that selectively hyperactivate PGE2 production, contributing to tumorigenesis and chemoresistance (Cebola2015Epigenetics). In gastric cancer, PTGS2 overexpression promotes tumorigenesis by inhibiting apoptosis and increasing angiogenesis (Sanz2006Cyclooxygenase).

In the context of inflammation, PTGS2 plays a critical role in the inflammatory response. Its overexpression is linked to inflammatory diseases, and its inhibition by nonsteroidal anti-inflammatory drugs (NSAIDs) has shown anti-neoplastic effects (Sanz2006Cyclooxygenase). However, the use of COX-2 inhibitors is associated with increased cardiovascular risks, highlighting the complex role of PTGS2 in disease (Cebola2015Epigenetics).

PTGS2 is also crucial for normal renal development. Deficiency in COX-2, the enzyme encoded by PTGS2, leads to significant renal abnormalities, including cystic dysplasia and impaired renal function, as observed in COX-2 null mice (Norwood2000Postnatal).

## Interactions
PTGS2, also known as COX-2, is involved in various protein-protein interactions that regulate its activity and stability. One significant interaction is with microsomal prostaglandin E synthase-1 (mPGES-1), which is closely associated with COX-2 in the endoplasmic reticulum (ER) membrane. This proximity facilitates the efficient transfer of prostaglandin H2 (PGH2) from COX-2 to mPGES-1, leading to the production of prostaglandin E2 (PGE2) during inflammation (Akasaka2015Relationship).

COX-2 also interacts with caveolin-1 (Cav-1) at the ER or nuclear envelope, which enhances its degradation through the endoplasmic reticulum-associated degradation (ERAD) pathway (Alexanian2017Cyclooxygenase). Additionally, COX-2 forms complexes with proteins such as ELMO1 and FYN. ELMO1 is associated with increased fibronectin gene expression in human mesangial cells, while FYN phosphorylates COX-2 at specific tyrosine residues, enhancing its activity and potentially contributing to disease progression (Alexanian2017Cyclooxygenase).

The enzyme is also subject to post-translational modifications, including s-nitrosylation, which involves interactions with nitric oxide synthase (NOS) and enhances COX-2's catalytic activity (Alexanian2017Cyclooxygenase). These interactions and modifications are crucial for understanding the regulation of COX-2 activity and its role in inflammatory and other pathophysiological processes.


## References


[1. (Akasaka2015Relationship) Hironari Akasaka, Shui-Ping So, and Ke-He Ruan. Relationship of the topological distances and activities between mpges-1 and cox-2 versus cox-1: implications of the different post-translational endoplasmic reticulum organizations of cox-1 and cox-2. Biochemistry, 54(23):3707–3715, June 2015. URL: http://dx.doi.org/10.1021/acs.biochem.5b00339, doi:10.1021/acs.biochem.5b00339. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/acs.biochem.5b00339)

[2. (Sanz2006Cyclooxygenase) Paloma Martin Sanz. Cyclooxygenase 2: understanding the pathophysiological role through genetically altered mouse models. Frontiers in Bioscience, 11(1):2876, 2006. URL: http://dx.doi.org/10.2741/2016, doi:10.2741/2016. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.2741/2016)

[3. (Norwood2000Postnatal) Victoria F. Norwood, Scott G. Morham, and Oliver Smithies. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney International, 58(6):2291–2300, December 2000. URL: http://dx.doi.org/10.1046/j.1523-1755.2000.00413.x, doi:10.1046/j.1523-1755.2000.00413.x. This article has 93 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1046/j.1523-1755.2000.00413.x)

[4. (Cebola2015Epigenetics) Inês Cebola, Joaquin Custodio, Mar Muñoz, Anna Díez-Villanueva, Laia Paré, Patricia Prieto, Susanna Aussó, Llorenç Coll-Mulet, Lisardo Boscá, Victor Moreno, and Miguel A. Peinado. Epigenetics override pro-inflammatory ptgs transcriptomic signature towards selective hyperactivation of pge2 in colorectal cancer. Clinical Epigenetics, July 2015. URL: http://dx.doi.org/10.1186/s13148-015-0110-4, doi:10.1186/s13148-015-0110-4. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13148-015-0110-4)

[5. (Tanabe2002Cyclooxygenase) Tadashi Tanabe and Norimitsu Tohnai. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins &amp; Other Lipid Mediators, 68–69:95–114, August 2002. URL: http://dx.doi.org/10.1016/s0090-6980(02)00024-2, doi:10.1016/s0090-6980(02)00024-2. This article has 307 citations.](https://doi.org/10.1016/s0090-6980(02)00024-2)

[6. (Williams1996Prostaglandin) C. S. Williams and R. N. DuBois. Prostaglandin endoperoxide synthase: why two isoforms? American Journal of Physiology-Gastrointestinal and Liver Physiology, 270(3):G393–G400, March 1996. URL: http://dx.doi.org/10.1152/ajpgi.1996.270.3.g393, doi:10.1152/ajpgi.1996.270.3.g393. This article has 52 citations.](https://doi.org/10.1152/ajpgi.1996.270.3.g393)

[7. (Valdes2008Genomewide) Ana M. Valdes, John Loughlin, Kirsten M. Timms, Joyce J.B. van Meurs, Lorraine Southam, Scott G. Wilson, Sally Doherty, Rik J. Lories, Frank P. Luyten, Alexander Gutin, Victor Abkevich, Dongliang Ge, Albert Hofman, André G. Uitterlinden, Deborah J. Hart, Feng Zhang, Guangju Zhai, Rainer J. Egli, Michael Doherty, Jerry Lanchbury, and Tim D. Spector. Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. The American Journal of Human Genetics, 82(6):1231–1240, June 2008. URL: http://dx.doi.org/10.1016/j.ajhg.2008.04.006, doi:10.1016/j.ajhg.2008.04.006. This article has 87 citations.](https://doi.org/10.1016/j.ajhg.2008.04.006)

[8. (Alexanian2017Cyclooxygenase) Anna Alexanian and Andrey Sorokin. Cyclooxygenase 2: protein-protein interactions and posttranslational modifications. Physiological Genomics, 49(11):667–681, November 2017. URL: http://dx.doi.org/10.1152/physiolgenomics.00086.2017, doi:10.1152/physiolgenomics.00086.2017. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.1152/physiolgenomics.00086.2017)

[9. (Narumiya1999Prostanoid) Shuh Narumiya, Yukihiko Sugimoto, and Fumitaka Ushikubi. Prostanoid receptors: structures, properties, and functions. Physiological Reviews, 79(4):1193–1226, January 1999. URL: http://dx.doi.org/10.1152/physrev.1999.79.4.1193, doi:10.1152/physrev.1999.79.4.1193. This article has 1924 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1152/physrev.1999.79.4.1193)

[10. (Santulli2014Hormonal) Pietro Santulli, Bruno Borghese, Jean-Christophe Noël, Isabelle Fayt, Vincent Anaf, Dominique de Ziegler, Frederic Batteux, Daniel Vaiman, and Charles Chapron. Hormonal therapy deregulates prostaglandin-endoperoxidase synthase 2 (ptgs2) expression in endometriotic tissues. The Journal of Clinical Endocrinology &amp; Metabolism, 99(3):881–890, March 2014. URL: http://dx.doi.org/10.1210/jc.2013-2950, doi:10.1210/jc.2013-2950. This article has 42 citations.](https://doi.org/10.1210/jc.2013-2950)